Chemed Reports First-Quarter 2015 Results
Consolidated operating results:
-
Revenue increased 5.1% to
$377 million -
GAAP Diluted EPS increased 25.0% to
$1.40 -
Adjusted Diluted EPS increased 16.7% to
$1.54
VITAS segment operating results:
-
Net Patient Revenue of
$270 million , an increase of 3.5% - Average Daily Census (ADC) of 14,824, an increase of 3.5%
- Admissions of 17,268, an increase of 5.6%
-
Net Income, including litigation costs, of
$19.3 million , an increase of 6.4% -
Adjusted EBITDA of
$36.0 million , an increase of 5.9% - Adjusted EBITDA margin of 13.3%, an increase of 30 basis points
Roto-Rooter segment operating results:
-
Revenue of
$107 million , an increase of 9.3% -
Net Income of
$12.0 million , an increase of 19.7% -
Adjusted EBITDA of
$21.4 million , an increase of 21.3% - Adjusted EBITDA margin of 20.0%, an increase of 197 basis points
VITAS
Net revenue for VITAS was
In the first quarter of 2015, VITAS reversed
Of VITAS’ 35 unique
Average revenue per patient per day in the quarter, excluding the impact
of Medicare Cap, was
The first quarter of 2015 gross margin, excluding the impact of
Selling, general and administrative expense was
Roto-Rooter
Roto-Rooter’s plumbing and drain cleaning business generated sales of
Roto-Rooter’s gross margin in the quarter was 47.3%, an 88 basis point
improvement when compared to the first quarter of 2014. Adjusted EBITDA
in the first quarter of 2015 totaled
Chemed Consolidated
As of
In
Capital expenditures through
In the first quarter of 2015, Chemed’s Board of Directors authorized an
additional
Guidance for 2015
Full-year 2015 revenue growth for VITAS, prior to Medicare Cap, is
estimated to be in the range of 3% to 4%. Admissions in 2015 are
estimated to increase 4% and full-year Adjusted EBITDA margin, prior to
Medicare Cap, is estimated to be 14% to 15%. Medicare Cap billing
limitations for calendar year 2015 are estimated to be
Roto-Rooter is forecasted to achieve full-year 2015 revenue growth of 3% to 4%. This revenue estimate is based upon continued expansion in water restoration services coupled with increased job pricing of approximately 1%. Adjusted EBITDA margin for 2015 is estimated in the range of 19% to 20%.
Management estimates that full-year 2015 adjusted earnings per diluted
share, which excludes non-cash expense for stock options, costs related
to litigation, and other discrete items, will be in the range of
Conference Call
A taped replay of the conference call will be available beginning approximately 24 hours after the call's conclusion. It can be accessed by dialing (888) 286-8010 for U.S. and Canadian callers and (617) 801-6888 for international callers and will be available for one week following the live call. The replay pass code is 67403472. An archived webcast will also be available at www.chemed.com.
This press release contains information about Chemed’s EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS, which are not measures derived in
accordance with GAAP and which exclude components that are important to
understanding Chemed’s financial performance. In reporting its operating
results,
Forward-Looking Statements
Certain statements contained in this press release and the accompanying
tables are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "hope," "anticipate," "plan" and similar expressions identify
forward-looking statements, which speak only as of the date the
statement was made.
These risks and uncertainties arise from, among other things, possible
changes in regulations governing the hospice care or plumbing and drain
cleaning industries; periodic changes in reimbursement levels and
procedures under
CHEMED CORPORATION AND SUBSIDIARY COMPANIES |
||||||||||||
CONSOLIDATED STATEMENT OF INCOME | ||||||||||||
(in thousands, except per share data)(unaudited) |
||||||||||||
Three Months Ended March 31, | ||||||||||||
2015 |
2014 | |||||||||||
Service revenues and sales | $ | 376,652 | $ | 358,300 | ||||||||
Cost of services provided and goods sold | 268,885 | 257,819 | ||||||||||
Selling, general and administrative expenses (aa) | 58,588 | 55,671 | ||||||||||
Depreciation | 8,032 | 7,149 | ||||||||||
Amortization | 576 | 1,009 | ||||||||||
Total costs and expenses | 336,081 | 321,648 | ||||||||||
Income from operations | 40,571 | 36,652 | ||||||||||
Interest expense | (969 | ) | (3,815 | ) | ||||||||
Other income--net (bb) | 563 | 816 | ||||||||||
Income before income taxes | 40,165 | 33,653 | ||||||||||
Income taxes | (15,628 | ) | (13,079 | ) | ||||||||
Net income | $ | 24,537 | $ | 20,574 | ||||||||
Earnings Per Share |
||||||||||||
Net income | $ | 1.45 | $ | 1.17 | ||||||||
Average number of shares outstanding | 16,914 | 17,510 | ||||||||||
Diluted Earnings Per Share |
||||||||||||
Net income | $ | 1.40 | $ | 1.12 | ||||||||
Average number of shares outstanding | 17,466 | 18,305 | ||||||||||
(aa) | Selling, general and administrative ("SG&A") expenses comprise (in thousands): | |||||||||||
Three Months Ended March 31, | ||||||||||||
2015 | 2014 | |||||||||||
SG&A expenses before long-term incentive compensation and the impact of market value gains related to deferred compensation plans |
$ | 56,704 | $ | 54,136 | ||||||||
Market value gains related to deferred compensation plans | 950 | 1,162 | ||||||||||
Long-term incentive compensation | 934 | 373 | ||||||||||
Total SG&A expenses | $ | 58,588 | $ | 55,671 | ||||||||
(bb) | Other income--net comprises (in thousands): | |||||||||||
Three Months Ended March 31, | ||||||||||||
2015 | 2014 | |||||||||||
Market value gains related to deferred compensation plans | $ | 950 | $ | 1,162 | ||||||||
Gain/(loss) on disposal of property and equipment | 48 | (278 | ) | |||||||||
Interest income | 44 | (50 | ) | |||||||||
Other | (479 | ) | (18 | ) | ||||||||
Total other income--net | $ | 563 | $ | 816 | ||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES |
|||||||||||||
CONSOLIDATED BALANCE SHEET | |||||||||||||
(in thousands, except per share data)(unaudited) |
|||||||||||||
March 31, | |||||||||||||
2015 |
2014 | ||||||||||||
Assets |
|||||||||||||
Current assets | |||||||||||||
Cash and cash equivalents | $ | 28,335 | $ | 39,479 | |||||||||
Accounts receivable less allowances | 145,757 | 116,152 | |||||||||||
Inventories | 6,166 | 6,676 | |||||||||||
Current deferred income taxes | 16,926 | 13,769 | |||||||||||
Prepaid income taxes | 1,279 | 3,406 | |||||||||||
Prepaid expenses | 10,023 | 18,930 | |||||||||||
Total current assets | 208,486 | 198,412 | |||||||||||
Investments of deferred compensation plans held in trust | 52,075 | 45,732 | |||||||||||
Properties and equipment, at cost less accumulated depreciation | 104,796 | 93,575 | |||||||||||
Identifiable intangible assets less accumulated amortization | 55,901 | 56,276 | |||||||||||
Goodwill | 466,576 | 466,961 | |||||||||||
Other assets | 7,843 | 7,664 | |||||||||||
Total Assets | $ | 895,677 | $ | 868,620 | |||||||||
Liabilities | |||||||||||||
Current liabilities | |||||||||||||
Accounts payable | $ | 43,618 | $ | 38,599 | |||||||||
Current portion of long-term debt | 6,875 | 185,825 | |||||||||||
Income taxes | 13,033 | 3,967 | |||||||||||
Accrued insurance | 42,498 | 39,391 | |||||||||||
Accrued compensation | 43,578 | 38,233 | |||||||||||
Accrued legal | 1,115 | 7,154 | |||||||||||
Other current liabilities | 20,853 | 24,682 | |||||||||||
Total current liabilities | 171,570 | 337,851 | |||||||||||
Deferred income taxes | 28,794 | 28,232 | |||||||||||
Long-term debt | 154,375 | - | |||||||||||
Deferred compensation liabilities | 51,407 | 45,498 | |||||||||||
Other liabilities | 12,989 | 11,106 | |||||||||||
Total Liabilities | 419,135 | 422,687 | |||||||||||
Stockholders' Equity | |||||||||||||
Capital stock | 33,516 | 32,621 | |||||||||||
Paid-in capital | 553,565 | 504,883 | |||||||||||
Retained earnings | 791,970 | 703,385 | |||||||||||
Treasury stock, at cost | (904,825 | ) | (797,141 | ) | |||||||||
Deferred compensation payable in Company stock | 2,316 | 2,185 | |||||||||||
Total Stockholders' Equity | 476,542 | 445,933 | |||||||||||
Total Liabilities and Stockholders' Equity | $ | 895,677 | $ | 868,620 | |||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||
CONSOLIDATED STATEMENT OF CASH FLOWS | ||||||||||||||
(in thousands)(unaudited) | ||||||||||||||
Three Months Ended | ||||||||||||||
March 31, | ||||||||||||||
2015 |
2014 | |||||||||||||
Cash Flows from Operating Activities | ||||||||||||||
Net income | $ | 24,537 | $ | 20,574 | ||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||||||||
Depreciation and amortization | 8,608 | 8,158 | ||||||||||||
Provision for uncollectible accounts receivable | 3,804 | 3,304 | ||||||||||||
Provision for deferred income taxes | (2,734 | ) | 6,841 | |||||||||||
Stock option expense | 1,444 | 1,309 | ||||||||||||
Noncash long-term incentive compensation | 934 | 373 | ||||||||||||
Amortization of debt issuance costs | 131 | 337 | ||||||||||||
Amortization of discount on convertible notes | - | 2,261 | ||||||||||||
Changes in operating assets and liabilities, excluding amounts acquired in business combinations: |
||||||||||||||
Increase in accounts receivable | (24,926 | ) | (27,700 | ) | ||||||||||
Decrease in inventories | 2 | 27 | ||||||||||||
Decrease/(increase) in prepaid expenses | 1,433 | (1,112 | ) | |||||||||||
Decrease in accounts payable and other current liabilities | (9,538 | ) | (32,561 | ) | ||||||||||
Increase in income taxes | 11,696 | 5,322 | ||||||||||||
Increase in other assets | (2,815 | ) | (1,069 | ) | ||||||||||
Increase in other liabilities | 2,569 | 3,080 | ||||||||||||
Excess tax benefit on share-based compensation | (2,900 | ) | (1,399 | ) | ||||||||||
Other sources | 129 | 409 | ||||||||||||
Net cash provided/(used) by operating activities | 12,374 | (11,846 | ) | |||||||||||
Cash Flows from Investing Activities | ||||||||||||||
Capital expenditures | (8,553 | ) | (8,131 | ) | ||||||||||
Business combinations | - | (250 | ) | |||||||||||
Other sources | 351 | 29 | ||||||||||||
Net cash used by investing activities | (8,202 | ) | (8,352 | ) | ||||||||||
Cash Flows from Financing Activities | ||||||||||||||
Proceeds from long-term debt | 37,200 | - | ||||||||||||
Payments on long-term debt | (23,450 | ) | - | |||||||||||
Capital stock surrendered to pay taxes on stock-based compensation | (5,464 | ) | (2,916 | ) | ||||||||||
Proceeds from exercise of stock options | 4,899 | 13,193 | ||||||||||||
Dividends paid | (3,743 | ) | (3,303 | ) | ||||||||||
Excess tax benefit on share-based compensation | 2,900 | 1,399 | ||||||||||||
Increase/(decrease) in cash overdrafts payable | (1,528 | ) | 369 | |||||||||||
Purchase of treasury stock | - | (32,982 | ) | |||||||||||
Other uses | (783 | ) | (501 | ) | ||||||||||
Net cash provided/ (used) by financing activities | 10,031 | (24,741 | ) | |||||||||||
Increase/(Decrease) in Cash and Cash Equivalents | 14,203 | (44,939 | ) | |||||||||||
Cash and cash equivalents at beginning of year | 14,132 | 84,418 | ||||||||||||
Cash and cash equivalents at end of period | $ | 28,335 | $ | 39,479 | ||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||
CONSOLIDATING STATEMENT OF INCOME | ||||||||||||||||||||||
FOR THE THREE MONTHS ENDED MARCH 31, 2015 AND 2014 | ||||||||||||||||||||||
(in thousands)(unaudited) |
||||||||||||||||||||||
Chemed | ||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||||||||
2015 |
||||||||||||||||||||||
Service revenues and sales | $ | 269,613 | $ | 107,039 | $ | - | $ | 376,652 | ||||||||||||||
Cost of services provided and goods sold | 212,495 | 56,390 | - | 268,885 | ||||||||||||||||||
Selling, general and administrative expenses (a) | 21,971 | 28,761 | 7,856 | 58,588 | ||||||||||||||||||
Depreciation | 4,785 | 3,094 | 153 | 8,032 | ||||||||||||||||||
Amortization | 167 | 108 | 301 | 576 | ||||||||||||||||||
Total costs and expenses | 239,418 | 88,353 | 8,310 | 336,081 | ||||||||||||||||||
Income/(loss) from operations | 30,195 | 18,686 | (8,310 | ) | 40,571 | |||||||||||||||||
Interest expense (a) | (57 | ) | (96 | ) | (816 | ) | (969 | ) | ||||||||||||||
Intercompany interest income/(expense) | 1,726 | 838 | (2,564 | ) | - | |||||||||||||||||
Other income/(expense)—net | (433 | ) | 46 | 950 | 563 | |||||||||||||||||
Income/(loss) before income taxes | 31,431 | 19,474 | (10,740 | ) | 40,165 | |||||||||||||||||
Income taxes (a) | (12,116 | ) | (7,466 | ) | 3,954 | (15,628 | ) | |||||||||||||||
Net income/(loss) | $ | 19,315 | $ | 12,008 | $ | (6,786 | ) | $ | 24,537 | |||||||||||||
2014 | ||||||||||||||||||||||
Service revenues and sales | $ | 260,412 | $ | 97,888 | $ | - | $ | 358,300 | ||||||||||||||
Cost of services provided and goods sold | 205,392 | 52,427 | - | 257,819 | ||||||||||||||||||
Selling, general and administrative expenses (b) | 21,714 | 27,181 | 6,776 | 55,671 | ||||||||||||||||||
Depreciation | 4,614 | 2,399 | 136 | 7,149 | ||||||||||||||||||
Amortization | 419 | 145 | 445 | 1,009 | ||||||||||||||||||
Total costs and expenses | 232,139 | 82,152 | 7,357 | 321,648 | ||||||||||||||||||
Income/(loss) from operations | 28,273 | 15,736 | (7,357 | ) | 36,652 | |||||||||||||||||
Interest expense (b) | (56 | ) | (97 | ) | (3,662 | ) | (3,815 | ) | ||||||||||||||
Intercompany interest income/(expense) | 1,344 | 649 | (1,993 | ) | - | |||||||||||||||||
Other income/(expense)-net | (293 | ) | (59 | ) | 1,168 | 816 | ||||||||||||||||
Income/(loss) before income taxes | 29,268 | 16,229 | (11,844 | ) | 33,653 | |||||||||||||||||
Income taxes (b) | (11,109 | ) | (6,196 | ) | 4,226 | (13,079 | ) | |||||||||||||||
Net income/(loss) | $ | 18,159 | $ | 10,033 | $ | (7,618 | ) | $ | 20,574 | |||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | ||||||||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||
CONSOLIDATING SUMMARY OF EBITDA | |||||||||||||||||||||||
FOR THE THREE MONTHS ENDED MARCH 31, 2015 AND 2014 | |||||||||||||||||||||||
(in thousands)(unaudited) | |||||||||||||||||||||||
Chemed | |||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||
2015 |
|||||||||||||||||||||||
Net income/(loss) | $ | 19,315 | $ | 12,008 | $ | (6,786 | ) | $ | 24,537 | ||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Interest expense | 57 | 96 | 816 | 969 | |||||||||||||||||||
Income taxes | 12,116 | 7,466 | (3,954 | ) | 15,628 | ||||||||||||||||||
Depreciation | 4,785 | 3,094 | 153 | 8,032 | |||||||||||||||||||
Amortization | 167 | 108 | 301 | 576 | |||||||||||||||||||
EBITDA | 36,440 | 22,772 | (9,470 | ) | 49,742 | ||||||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Intercompany interest income/(expense) | (1,726 | ) | (838 | ) | 2,564 | - | |||||||||||||||||
Interest income | (34 | ) | (10 | ) | - | (44 | ) | ||||||||||||||||
Expenses related to OIG investigation | 1,274 | - | - | 1,274 | |||||||||||||||||||
Expenses related to litigation settlements | - | 5 | - | 5 | |||||||||||||||||||
Advertising cost adjustment (c) | - | (506 | ) | - | (506 | ) | |||||||||||||||||
Stock option expense | - | - | 1,444 | 1,444 | |||||||||||||||||||
Long-term incentive compensations | - | - | 934 | 934 | |||||||||||||||||||
Adjusted EBITDA | $ | 35,954 | $ | 21,423 | $ | (4,528 | ) | $ | 52,849 | ||||||||||||||
2014 | |||||||||||||||||||||||
Net income/(loss) | $ | 18,159 | $ | 10,033 | $ | (7,618 | ) | $ | 20,574 | ||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Interest expense | 56 | 97 | 3,662 | 3,815 | |||||||||||||||||||
Income taxes | 11,109 | 6,196 | (4,226 | ) | 13,079 | ||||||||||||||||||
Depreciation | 4,614 | 2,399 | 136 | 7,149 | |||||||||||||||||||
Amortization | 419 | 145 | 445 | 1,009 | |||||||||||||||||||
EBITDA | 34,357 | 18,870 | (7,601 | ) | 45,626 | ||||||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Intercompany interest income/(expense) | (1,344 | ) | (649 | ) | 1,993 | - | |||||||||||||||||
Interest income | 64 | (8 | ) | (6 | ) | 50 | |||||||||||||||||
Expenses related to OIG investigation | 748 | - | - | 748 | |||||||||||||||||||
Expenses related to litigation settlements | 113 | 193 | - | 306 | |||||||||||||||||||
Acquisition expenses | 1 | - | - | 1 | |||||||||||||||||||
Advertising cost adjustment (c) | - | (741 | ) | - | (741 | ) | |||||||||||||||||
Stock option expense | - | - | 1,309 | 1,309 | |||||||||||||||||||
Long-term incentive compensations | - | - | 373 | 373 | |||||||||||||||||||
Adjusted EBITDA | $ | 33,939 | $ | 17,665 | $ | (3,932 | ) | $ | 47,672 | ||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | |||||||||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||
RECONCILIATION OF ADJUSTED NET INCOME | |||||||||||||
(in thousands, except per share data)(unaudited) | |||||||||||||
Three Months Ended March 31, | |||||||||||||
2015 | 2014 | ||||||||||||
Net income as reported | $ | 24,537 | $ | 20,574 | |||||||||
Add after-tax cost of: | |||||||||||||
Stock option expense | 910 | 822 | |||||||||||
Expenses related to OIG investigation | 790 | 464 | |||||||||||
Long-term incentive compensation | 591 | 236 | |||||||||||
Expenses related to litigation settlements | 3 | 187 | |||||||||||
Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes |
- | 1,429 | |||||||||||
Acquisition expenses | - | 1 | |||||||||||
Adjusted net income | $ | 26,831 | $ | 23,713 | |||||||||
Diluted Earnings Per Share As Reported | |||||||||||||
Net income | $ | 1.40 | $ | 1.12 | |||||||||
Average number of shares outstanding | 17,466 | 18,305 | |||||||||||
Adjusted Diluted Earnings Per Share | |||||||||||||
Adjusted net income | $ |
1.54 |
$ |
1.32 |
|||||||||
Adjusted average number of shares outstanding (d) |
17,466 |
18,019 |
|||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | |||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||
OPERATING STATISTICS FOR VITAS SEGMENT | |||||||||||||||
(unaudited) | |||||||||||||||
Three Months Ended March 31, | |||||||||||||||
OPERATING STATISTICS |
2015 |
2014 | |||||||||||||
Net revenue ($000) (e) | |||||||||||||||
Homecare | $ | 204,541 | $ | 195,397 | |||||||||||
Inpatient | 26,716 | 25,993 | |||||||||||||
Continuous care | 38,191 | 38,175 | |||||||||||||
Total before Medicare cap allowance | $ | 269,448 | $ | 259,565 | |||||||||||
Medicare cap allowance | 165 | 847 | |||||||||||||
Total | $ | 269,613 | $ | 260,412 | |||||||||||
Net revenue as a percent of total before Medicare cap allowance |
|||||||||||||||
Homecare | 75.9 | % | 75.3 | % | |||||||||||
Inpatient | 9.9 | 10.0 | |||||||||||||
Continuous care | 14.2 | 14.7 | |||||||||||||
Total before Medicare cap allowance | 100.0 | 100.0 | |||||||||||||
Medicare cap allowance | 0.1 | 0.3 | |||||||||||||
Total | 100.1 | % | 100.3 | % | |||||||||||
Average daily census ("ADC") (days) | |||||||||||||||
Homecare | 10,877 | 10,476 | |||||||||||||
Nursing home | 2,920 | 2,828 | |||||||||||||
Routine homecare | 13,797 | 13,304 | |||||||||||||
Inpatient | 440 | 437 | |||||||||||||
Continuous care | 587 | 576 | |||||||||||||
Total | 14,824 | 14,317 | |||||||||||||
Total Admissions | 17,268 | 16,353 | |||||||||||||
Total Discharges | 16,990 | 16,002 | |||||||||||||
Average length of stay (days) | 79.0 | 81.1 | |||||||||||||
Median length of stay (days) | 13.0 | 14.0 | |||||||||||||
ADC by major diagnosis | |||||||||||||||
Neurological | 23.7 | % | 39.2 | % | |||||||||||
Cerebro | 28.0 | 5.5 | |||||||||||||
Cancer | 16.9 | 17.3 | |||||||||||||
Cardio | 17.8 | 14.7 | |||||||||||||
Respiratory | 7.8 | 3.3 | |||||||||||||
|
Other | 5.8 | 20.0 | ||||||||||||
Total | 100.0 | % | 100.0 | % | |||||||||||
Admissions by major diagnosis | |||||||||||||||
Neurological | 12.9 | % | 21.8 | % | |||||||||||
Cerebro | 18.6 | 6.7 | |||||||||||||
Cancer | 30.6 | 32.4 | |||||||||||||
Cardio | 15.8 | 13.8 | |||||||||||||
Respiratory | 10.8 | 9.9 | |||||||||||||
Other | 11.3 | 15.4 | |||||||||||||
Total | 100.0 | % | 100.0 | % | |||||||||||
Direct patient care margins (f) | |||||||||||||||
Routine homecare | 52.7 | % | 52.8 | % | |||||||||||
Inpatient | 8.4 | 4.2 | |||||||||||||
Continuous care | 15.9 | 16.6 | |||||||||||||
Homecare margin drivers (dollars per patient day) | |||||||||||||||
Labor costs | $ | 57.21 | $ | 55.44 | |||||||||||
Drug costs | 6.50 | 7.24 | |||||||||||||
Home medical equipment | 6.41 | 6.61 | |||||||||||||
Medical supplies | 2.92 | 3.22 | |||||||||||||
Inpatient margin drivers (dollars per patient day) | |||||||||||||||
Labor costs | $ | 339.37 | $ | 349.71 | |||||||||||
Continuous care margin drivers (dollars per patient day) | |||||||||||||||
Labor costs | $ | 587.63 | $ | 593.77 | |||||||||||
Bad debt expense as a percent of revenues | 1.0 | % | 1.0 | % | |||||||||||
Accounts receivable -- | |||||||||||||||
Days of revenue outstanding- excluding unapplied Medicare payments | 41.3 | 42.7 | |||||||||||||
Days of revenue outstanding- including unapplied Medicare payments | 38.1 | 33.8 | |||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | |||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES |
||||||||||||||||||||||
FOOTNOTES TO FINANCIAL STATEMENTS |
||||||||||||||||||||||
FOR THE THREE MONTHS ENDED MARCH 31, 2015 AND 2014 | ||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||
(a) |
Included in the results of operations for the three months ended March 31, 2015, are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands): |
|||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Total | |||||||||||||||||||
Selling, general and administrative expenses | ||||||||||||||||||||||
Expenses related to OIG investigation | $ | (1,274 | ) | $ | - | $ | - | $ | (1,274 | ) | ||||||||||||
Expenses related to litigation settlements | - | (5 | ) | - | (5 | ) | ||||||||||||||||
Stock option expense | - | - | (1,444 | ) | (1,444 | ) | ||||||||||||||||
Long-term incentive compensation | - | - | (934 | ) | (934 | ) | ||||||||||||||||
Pretax impact on earnings | (1,274 | ) | (5 | ) | (2,378 | ) | (3,657 | ) | ||||||||||||||
Income tax benefit/(charge) on the above | 484 | 2 | 877 | 1,363 | ||||||||||||||||||
After-tax impact on earnings | $ | (790 | ) | $ | (3 | ) | $ | (1,501 | ) | $ | (2,294 | ) | ||||||||||
(b) |
Included in the results of operations for the three months ended March 31, 2014, are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands): |
|||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Total | |||||||||||||||||||
Selling, general and administrative expenses | ||||||||||||||||||||||
Expenses related to OIG investigation | $ | (748 | ) | $ | - | $ | - | $ | (748 | ) | ||||||||||||
Expenses related to litigation settlements | (113 | ) | (193 | ) | - | (306 | ) | |||||||||||||||
Acquisition expenses | (1 | ) | - | - | (1 | ) | ||||||||||||||||
Stock option expense | - | - | (1,309 | ) | (1,309 | ) | ||||||||||||||||
Long-term incentive compensation | - | - | (373 | ) | (373 | ) | ||||||||||||||||
Interest expense | ||||||||||||||||||||||
Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes |
- | - | (2,259 | ) | (2,259 | ) | ||||||||||||||||
Pretax impact on earnings | (862 | ) | (193 | ) | (3,941 | ) | (4,996 | ) | ||||||||||||||
Income tax benefit/(charge) on the above | 327 | 76 | 1,454 | 1,857 | ||||||||||||||||||
After-tax impact on earnings | $ | (535 | ) | $ | (117 | ) | $ | (2,487 | ) | $ | (3,139 | ) | ||||||||||
(c) |
Under Generally Accepted Accounting Principles ("GAAP"), the Roto-Rooter segment expenses all advertising, including the cost of telephone directories, immediately upon the initial release of the advertising. Telephone directories are generally in circulation 12 months. If a directory is in circulation for a time period greater or less than 12 months, the publisher adjusts the directory billing for the change in billing period. The timing of when a telephone directory is published can and does fluctuate significantly on a quarterly basis. This "direct expensing" results in significant fluctuations in quarterly advertising expense. In the first quarters of 2015 and 2014, GAAP advertising expense for Roto-Rooter totaled $6,067,000 and $6,515,000, respectively. If the expense of the telephone directories were spread over the periods they are in circulation, advertising expense for the first quarters of 2015 and 2014 would total $6,573,000 and $7,256,000, respectively. |
(d) |
Adjusted diluted average shares outstanding for 2014 excludes the estimated dilutive impact of the Convertible Notes (285,000 shares for the first quarter of 2014) as this impact was offset entirely by the Convertible Note Hedges when such conversion occurred in the second quarter of 2014. |
(e) |
VITAS has nine large (greater than 450 ADC), 17 medium (greater than 200 but less than 450 ADC) and 23 small (less than 200 ADC) hospice programs. Of VITAS' 35 unique Medicare provider numbers, 34 provider numbers have a Medicare cap cushion of 10% or greater during the current Medicare cap year and one provider number has a Medicare cap cushion between 0% and 5%. |
(f) | Amounts exclude indirect patient care and administrative costs, as well as Medicare Cap billing limitation. |
Source:
Chemed Corporation
David P. Williams, 513-762-6901